Veraxa Biotech AG was incorporated under Swiss law on June 25, 2025. The company is an oncology-focused biotechnology company with clinical programs in acute myeloid leukemia and proprietary platform technologies for the development of antibody-drug conjugates and T-cell adapters. The goal is to establish a pipeline of oncology programs designed to achieve efficacy for patients while minimizing side effects. 

VERAXA Biotech has appointed Raju Willener as its new Chief Financial Officer, effective immediately. Willener has over three decades of experience in financial leadership, including international capital markets, investment banking, and asset management. He will support the company's capital strategy, strategic opportunities, and development of its BiTAC technology platform and oncology pipeline. Willener previously served as CFO at Exentis Group AG, where he led M&A initiatives, financial strategy, and corporate functions. VERAXA is a developer of next-generation antibody-based cancer therapies.

Veraxa

VERAXA Biotech Appoints Raju Willener as CFO

Veraxa (VRXA) fell 10.80% in intraday trading after rising 15.03% on Friday, marking a reversal of the prior session's move.

Veraxa (VRXA) fell 10.80% intraday after rising 15.03% on Friday

Veraxa (VRXA) shares climbed 13.07% intraday after the company announced the immediate appointment of Raju Willener as chief financial officer. Willener brings over 30 years of global capital markets and corporate finance experience to support the firm's capital strategy and strategic opportunity evaluation.

Veraxa Shares Rise 13.07% After CFO Appointment

VERAXA Biotech has appointed Raju Willener as Chief Financial Officer, bringing over three decades of global capital markets and corporate finance experience. Willener will support the advancement of the company's pipeline of potential best-in-class therapies led by its BiTAC platform. He has held senior roles in investment banking, corporate finance, asset management, and strategic leadership across the US, Europe, and Asia. Willener's expertise will be valuable in optimizing VERAXA's capital strategy, evaluating strategic opportunities, and supporting disciplined execution and long-term shareholder value creation.

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

Veraxa Biotech has appointed Raju Willener as its Chief Financial Officer. Willener brings extensive experience in the biotech industry, having previously held roles at companies such as Biogen and Baxter International. As CFO, Willener will be responsible for overseeing the company's financial operations and strategies. The appointment is seen as a positive development for Veraxa, which is focused on developing novel therapies for various diseases. The company's stock, VRXA, has been on a downtrend recently, but this appointment could potentially boost investor confidence and drive the stock higher in the near term.

VRXA News